share_log

Cosmos Health Signs Expanded Exclusive Distribution Agreement With Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

Cosmos Health Signs Expanded Exclusive Distribution Agreement With Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

阿童木健康與Virax Biolabs簽署了擴展的獨家分銷協議,負責在沙特阿拉伯、阿聯酋、卡塔爾和科威特分銷禽流感病毒PCR檢測試劑盒。
Accesswire ·  01/23 20:35

CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has entered into a supplemental exclusive distribution agreement with Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax") to distribute Virax-branded Avian Influenza Virus Real-Time PCR Kits across all remaining Gulf Cooperation Council (GCC) countries, including Saudi Arabia, the United Arab Emirates (UAE), Qatar, and Kuwait.

伊利諾伊州芝加哥 / ACCESS Newswire / 2025年1月23日 / 阿童木健康公司("阿童木健康"或"公司")(納斯達克:COSM),一家多元化、垂直整合的全球醫療保健集團,專注於創新研發,擁有專有藥品和營養保健品牌,是醫療保健產品的製造商和分銷商,同時也是遠程醫療平台的運營商,今天宣佈與維拉克斯生物實驗室集團有限公司(納斯達克:VRAX)("維拉克斯")簽訂了一項補充獨家分銷協議,授權維拉克斯品牌的禽流感病毒實時PCR試劑盒在所有剩餘的海灣合作委員會(GCC)國家分銷,包括沙特阿拉伯、阿拉伯聯合酋長國(UAE)、卡塔爾和科威特。

The previous exclusive distribution agreement, announced on January 13, 2025, was limited to Oman and Bahrain. Under the new agreement, Cosmos Health is now authorized to import, sell, and distribute ViraxClear-branded kits throughout all GCC countries.

之前的獨家分銷協議於2025年1月13日宣佈,僅限於阿曼和巴林。根據新協議,阿童木健康現在被授權在所有GCC國家進口、賣出和分銷維拉克斯清品牌的試劑盒。

Greg Siokas, CEO of Cosmos Health, stated: "We are delighted to deepen our collaboration with Virax and contribute to effective public health responses throughout all GCC countries."

阿童木健康的首席執行官Greg Siokas表示:「我們很高興能夠加深與維拉克斯的合作,併爲所有GCC國家的公共衛生應對做出貢獻。」

About Cosmos Health Inc.

Cosmos Health Inc.(納斯達克:COSM)成立於2009年,總部位於內華達州,是一家全球健康醫療集團公司。公司擁有一系列專有藥品和保健品牌,包括Sky Premium Life,Mediterranation,bio-bebe和C-Sept。公司的子公司Cana Laboratories S.A.獲得歐洲GMP許可和歐洲藥品管理局認證,生產醫藥品、食品補充劑、化妝品、生物滅菌劑和醫療設備等產品,並經營歐盟內的銷售。此外,Cosmos Health還通過希臘和英國的子公司向零售藥店和批發經銷商銷售廣泛的藥品和非處方藥品,包括品牌仿製藥和OTC藥品。此外,該公司還與人工智能藥物再利用技術合作,專注於研發針對肥胖症、糖尿病和癌症等主要健康障礙的研發合作,並專注於研發新的專利營養保健品、特殊植物提取物、專有複合仿製藥和創新非處方藥品。Cosmos Health還通過收購總部位於德克薩斯州的ZipDoctor,Inc進入了遠程醫療領域。公司正在全球範圍內擴張,並在希臘的塞薩洛尼基和雅典、英國的哈洛等地設有辦事處和配送中心。 更多信息請訪問公司網站:,以及LinkedIn和X。

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at , , , , as well as LinkedIn and X.

阿童木健康公司(納斯達克:COSM),成立於2009年,註冊於內華達州,是一個多元化、垂直整合的全球醫療保健集團。公司擁有一系列自有藥品和營養保健品牌,包括Sky Premium Life、Mediterranation、bio-bebe、C-Sept和C-Scrub。通過其子公司Cana Laboratories S.A.,該公司在歐盟享有歐洲良好製造規範(GMP)許可並由歐洲藥品管理局(EMA)認證,生產藥品、食品補充劑、化妝品、殺生劑和醫療設備。此外,阿童木健康還通過其在希臘和英國的子公司,向零售藥店和批發分銷商分銷廣泛的藥品和非處方藥,包括品牌仿製藥和場外交易藥物。此外,公司還建立了研發合作關係,針對肥胖、糖尿病和癌症等重大健康障礙,藉助人工智能藥物再利用技術進行增強,並專注於新型專利營養保健品、特殊根提取物、自有複雜仿製藥及創新的非處方產品的研發。阿童木健康還通過收購總部位於美國德克薩斯州的ZipDoctor, Inc.進入遠程醫療領域。憑藉全球分銷平台,該公司目前正在歐洲、亞洲和北美擴展,並在希臘的塞薩洛尼基和雅典以及英國哈羅建立了辦事處和分銷中心。更多信息請訪問,,,,,以及LinkedIn和X。

About Virax Biolabs
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited is currently developing T-Cell-based test technologies with the intention of providing an immunology profiling platform. T-Cell testing can be particularly effective in the diagnosis and therapeutics of post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation. For more information, please visit .

關於Virax生物實驗室
Virax生物實驗室集團有限公司是一家創新的生物技術公司,專注於檢測免疫反應和病毒疾病的診斷。Virax生物實驗室集團有限公司目前正在開發基於T細胞的測試技術,旨在提供一個免疫學分類平台。T細胞測試在診斷和治療病毒後綜合症如長新冠及其他與免疫失調相關的慢性病症方面尤其有效。欲了解更多信息,請訪問。

Forward-Looking Statements

前瞻性聲明

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

除本新聞稿中包含的歷史信息外,此處描述的事項可能包含1933年《證券法》第27A條及1934年《證券交易法》第21E條所指的前瞻性聲明。以「相信」、「期待」、「預期」、「意圖」、「項目」、「估計」、「計劃」等詞語開頭、跟隨或包含這些詞語的語句,或未來或條件動詞如「將」、「應該」、「會」、「可能」和「可以」等,通常具有前瞻性,非歷史事實,儘管並非所有的前瞻性聲明都包含上述內容。這些陳述涉及未知風險和不確定性,可能會單獨或重大影響此處討論的事項,原因有多種,超出了公司的控制,包括但不限於公司籌集足夠資金以實施其商業計劃的能力,COVID-19大流行和烏克蘭戰爭對公司業務、運營及整體經濟的影響,以及公司成功開發和商業化其專有產品及技術的能力。提醒讀者,切勿對這些前瞻性聲明過分依賴,因爲實際結果可能與此處描述的前瞻性聲明大相徑庭。強烈建議讀者閱讀公司向美國證券交易委員會(SEC)提交的文件中列出的風險因素,這些文件可在SEC官方網站(www.sec.gov)上查閱。公司對於任何新的信息、未來事件或其他原因導致的前瞻性聲明的更新或修改不承擔任何意圖或義務。

Investor Relations Contact:

投資者關係聯繫:

BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653

BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653

SOURCE: Cosmos Health Inc.

資訊來源:Cosmos Health Inc.


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 321

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。